The functional benefit of anti-inflammatory aerosols in the lung periphery

Journal of Allergy and Clinical Immunology

Volumn 118, Issue 2, 2006, Pages 340-346

  Verbanck, Sylvia ^a   Schuermans, Daniël ^a   Paiva, Manuel ^b   Vincken, Walter ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Asthma; inhaled corticosteroids; small airways; ultrafine aerosols

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; LONG ACTING DRUG; SALBUTAMOL;

ADOLESCENT; ADULT; AEROSOL; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG TARGETING; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION; LUNG FUNCTION; LUNG PERFUSION; LUNG VENTILATION; MALE; MEDICAL ASSESSMENT; METERED DOSE INHALER; POWDER INHALER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPIROMETRY; VALIDATION STUDY;

ADOLESCENT; ADULT; AEROSOL PROPELLANTS; AEROSOLS; AGED; ANTI-INFLAMMATORY AGENTS; ASTHMA; BECLOMETHASONE; BRONCHODILATOR AGENTS; BUDESONIDE; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; SPIROMETRY;

EID: 33746563608     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.04.056     Document Type: Article

References (26)

1. Global Initiative for Asthma. NHLBI/WHO Workshop Report. Global strategy for asthma management and prevention. National Institutes of Health (1995), National Heart, Lung, and Blood Institute, Bethesda (MD) Publication #95-3659
2. Tulic M.K., and Hamid Q. The role of the distal lung in asthma. Semin Respir Crit Care Med 23 (2002) 347-360
3. Leach C.L., Davidson P.J., and Boudreau R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 12 (1998) 1346-1353
4. Leach C.L., Davidson P.J., Hasselquist B.E., and Boudreau R.J. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 122 (2002) 510-516
5. Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 104 (1999) S250-S252
6. Worth H., Muir J.F., and Pieters W.R. Comparison of hydrofluoroalkane-beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control. Respiration 68 (2001) 517-526
7. Reichel W., Dahl R., Ringdal N., Zetterstrom O., van den Elshout F.J., and Laitinen L.A. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma. Int J Clin Pract 55 (2001) 100-106
8. Ederle K. Multicentre Study Group. Improved control of asthma symptoms with a reduced dose of HFA-BDP extrafine aerosol: an open-label, randomised study. Eur Rev Med Pharmacol Sci 7 (2003) 45-55
9. Davies R.J., Stampone P., and O'Connor B.J. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 92 suppl A (1998) 23-31
10. Hampel F., Lisberg E., and Guerin J.C. Effectiveness of low doses (50 and 100 microg b.i.d) of beclomethasone dipropionate delivered as a CFC-free extrafine aerosol in adults with mild to moderate asthma. Study Group. J Asthma 37 (2000) 389-398
11. Fireman P., Prenner B.M., Vincken W., Demedts M., Mol S.J., and Cohen R.M. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann Allergy Asthma Immunol 86 (2001) 557-565
12. Fowler S.J., Currie G.P., and Lipworth B.J. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. J Allergy Clin Immunol 109 (2002) 929-935
13. Lipworth B.J. The comparative safety/efficacy ratio of HFA-BDP. Respir Med 94 suppl D (2000) S21-S26
14. Thongngarm T., Silkoff P.E., Kossack W.S., and Nelson H.S. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma 42 (2005) 257-263
15. Molimard M., Martinat Y., Rogeaux Y., Moyse D., Pello J.Y., and Giraud V. Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. Respir Med 99 (2005) 770-778
16. Busse W.W., Brazinsky S., Jacobson K., Stricker W., Schmitt K., Vanden Burgt J., et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 104 (1999) 1215-1222
17. Goldin J.G., Tashkin D.P., Kleerup E.C., Greaser L.E., Haywood U.M., Sayre J.W., et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 104 (1999) S258-S267
18. Marshall B.G., Wangoo A., Harrison L.I., Young D.B., and Shaw R.J. Tumour necrosis factor-alpha production in human alveolar macrophages: modulation by inhaled corticosteroid. Eur Respir J 15 (2000) 764-770
19. Verbanck S., Schuermans D., Van Muylem A., Paiva M., Noppen M., and Vincken W. Ventilation distribution during histamine provocation. J Appl Physiol 83 (1997) 1907-1916
20. Verbanck S., Schuermans D., Paiva M., and Vincken W. Nonreversible conductive airway ventilation heterogeneity in mild asthma. J Appl Physiol 94 (2003) 1380-1386
21. Verbanck S., Schuermans D., Noppen M., Van Muylem A., Paiva M., and Vincken W. Evidence of acinar airway involvement in asthma. Am J Respir Crit Care Med 159 (1999) 1545-1550
22. Verbanck S., Schuermans D., Meysman M., Paiva M., and Vincken W. Noninvasive assessment of airway alterations in smokers: the small airways revisited. Am J Respir Crit Care Med 170 (2004) 414-419
23. Juniper E.F., Price D.B., Stampone P.A., Creemers J.P., Mol S.J., and Fireman P. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 121 (2002) 1824-1832
24. Sutherland E.R., Martin R.J., Bowler R.P., Zhang Y., Rex M.D., and Kraft M. Physiologic correlates of distal lung inflammation in asthma. J Allergy Clin Immunol 113 (2004) 1046-1050
25. Borgstrom L., Bondesson E., Moren F., Trofast E., and Newman S.P. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 7 (1994) 69-73
26. Ross D.L., and Schultz R.K. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. J Aerosol Med 9 (1996) 215-226